Global Targeted PSMA Radionuclide Drug Conjugates Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Targeted PSMA Radionuclide Drug Conjugates market size was valued at US$ 2052 million in 2025 and is forecast to a readjusted size of US$ 3466 million by 2032 with a CAGR of 7.5% during review period.
Targeted PSMA Radionuclide Drug Conjugates are precision radiotherapeutics designed to selectively deliver therapeutic radioisotopes to tumor tissue by targeting prostate-specific membrane antigen, or PSMA. These products are typically composed of a PSMA-targeting small molecule or ligand, a chelator, and a therapeutic radionuclide. Among current commercialized and clinical-stage products, 177Lu-labeled agents are the most mature, while alpha-emitting candidates such as 225Ac-based products are still largely in clinical development or early-stage application. This category is primarily used for the treatment of PSMA-positive advanced prostate cancer, especially metastatic castration-resistant prostate cancer, or mCRPC. Upstream segments mainly include targeting ligands and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of hospitals with nuclear medicine capabilities, cancer centers, specialty treatment networks, and radiopharmaceutical distribution systems. On a commercial-market basis, the global market in 2025 remained centered on Novartis? Pluvicto, and the industry as a whole continued to show the characteristics of limited marketed products, an active clinical pipeline, and simultaneous technical and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized targeted PSMA radionuclide drug conjugates is estimated to be in the range of 55%-70%.
At present, the targeted PSMA radionuclide drug conjugate industry is in a stage driven by a limited number of commercialized products while accelerating into broader treatment settings. As the leading marketed products gradually move toward earlier lines of therapy, the sector is shifting from late-line clinical validation to a phase characterized by indication expansion and platform-based commercialization. This indicates that both the clinical value and commercial feasibility of the category are continuing to strengthen. Overall, market attention, capital investment, and pipeline activity are all increasing, and the industry is evolving from isolated product breakthroughs toward sustained competition centered on platform capability and indication expansion.
From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term because of its relatively mature clinical pathway, more established industrial infrastructure, and stronger commercialization foundation. At the same time, however, the industry is moving from competition around individual products to competition around platform capability. Future development is likely to focus not only on new ligand structures, combination regimens, and earlier treatment settings, but also on accelerated deployment of alpha-emitter approaches such as 225Ac in pursuit of stronger biological effects and differentiated therapeutic value. As leading companies continue to broaden their radioligand therapy portfolios, targeted PSMA drugs are likely to evolve from a single advanced prostate cancer therapy into a core component of broader radiopharmaceutical oncology platforms.
From an industrialization perspective, supply chain and manufacturing systems will be the key variables determining how quickly the industry can scale. Compared with conventional oncology drugs, targeted PSMA radionuclide drug conjugates place much higher demands on isotope supply, specialized manufacturing facilities, quality release, time-sensitive distribution, and hospital nuclear medicine capabilities. In the future, leading companies are expected to continue strengthening delivery resilience by expanding radiopharmaceutical production sites, building regional manufacturing networks, and increasing treatment-center coverage. As a result, competition will no longer be limited to the drug itself, but will increasingly become competition in integrated capabilities spanning product, manufacturing, logistics, and hospital access. In other words, companies that establish stable isotope access and strong treatment networks earlier will be better positioned in the commercialization phase.
Nevertheless, the industry still faces several constraints. Stable isotope supply, the construction cycle of dedicated capacity, and the availability of specialized treatment centers remain practical bottlenecks to market expansion. In addition, patient treatment pathways usually rely on PSMA imaging selection and supporting nuclear medicine infrastructure, while reimbursement systems, hospital access, and treatment standards differ significantly across countries and regions, making global market expansion uneven. As the category moves into earlier treatment settings and addresses a broader patient population, requirements for safety management, treatment standardization, and long-term follow-up data will also continue to rise. Overall, targeted PSMA radionuclide drug conjugates offer clear long-term growth potential, but future expansion is more likely to be gradual and system-driven, supported jointly by clinical evidence, supply assurance, and healthcare infrastructure development, rather than by rapid short-term scaling.
This report is a detailed and comprehensive analysis for global Targeted PSMA Radionuclide Drug Conjugates market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Targeted PSMA Radionuclide Drug Conjugates market size and forecasts, in consumption value ($ Million), 2021-2032
Global Targeted PSMA Radionuclide Drug Conjugates market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Targeted PSMA Radionuclide Drug Conjugates market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Targeted PSMA Radionuclide Drug Conjugates market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Targeted PSMA Radionuclide Drug Conjugates market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Targeted PSMA Radionuclide Drug Conjugates product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Targeted PSMA Radionuclide Drug Conjugates, with revenue, gross margin, and global market share of Targeted PSMA Radionuclide Drug Conjugates from 2021 to 2026.
Chapter 3, the Targeted PSMA Radionuclide Drug Conjugates competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Targeted PSMA Radionuclide Drug Conjugates market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Targeted PSMA Radionuclide Drug Conjugates.
Chapter 13, to describe Targeted PSMA Radionuclide Drug Conjugates research findings and conclusion.
Targeted PSMA Radionuclide Drug Conjugates are precision radiotherapeutics designed to selectively deliver therapeutic radioisotopes to tumor tissue by targeting prostate-specific membrane antigen, or PSMA. These products are typically composed of a PSMA-targeting small molecule or ligand, a chelator, and a therapeutic radionuclide. Among current commercialized and clinical-stage products, 177Lu-labeled agents are the most mature, while alpha-emitting candidates such as 225Ac-based products are still largely in clinical development or early-stage application. This category is primarily used for the treatment of PSMA-positive advanced prostate cancer, especially metastatic castration-resistant prostate cancer, or mCRPC. Upstream segments mainly include targeting ligands and precursors, chelators, radioisotope production and purification, sterile radiopharmaceutical filling, and specialized cold-chain logistics, while downstream customers mainly consist of hospitals with nuclear medicine capabilities, cancer centers, specialty treatment networks, and radiopharmaceutical distribution systems. On a commercial-market basis, the global market in 2025 remained centered on Novartis? Pluvicto, and the industry as a whole continued to show the characteristics of limited marketed products, an active clinical pipeline, and simultaneous technical and supply-chain barriers. Because these products combine the economics of innovative oncology drugs with the operational barriers of radiopharmaceutical manufacturing, including isotope supply, dedicated facilities, quality-release requirements, and specialized distribution, gross margin is generally higher than that of conventional small-molecule drugs and standard injectables. In 2025, the gross margin of commercialized targeted PSMA radionuclide drug conjugates is estimated to be in the range of 55%-70%.
At present, the targeted PSMA radionuclide drug conjugate industry is in a stage driven by a limited number of commercialized products while accelerating into broader treatment settings. As the leading marketed products gradually move toward earlier lines of therapy, the sector is shifting from late-line clinical validation to a phase characterized by indication expansion and platform-based commercialization. This indicates that both the clinical value and commercial feasibility of the category are continuing to strengthen. Overall, market attention, capital investment, and pipeline activity are all increasing, and the industry is evolving from isolated product breakthroughs toward sustained competition centered on platform capability and indication expansion.
From the perspective of technology and product evolution, the 177Lu route is expected to remain the mainstream direction in the medium term because of its relatively mature clinical pathway, more established industrial infrastructure, and stronger commercialization foundation. At the same time, however, the industry is moving from competition around individual products to competition around platform capability. Future development is likely to focus not only on new ligand structures, combination regimens, and earlier treatment settings, but also on accelerated deployment of alpha-emitter approaches such as 225Ac in pursuit of stronger biological effects and differentiated therapeutic value. As leading companies continue to broaden their radioligand therapy portfolios, targeted PSMA drugs are likely to evolve from a single advanced prostate cancer therapy into a core component of broader radiopharmaceutical oncology platforms.
From an industrialization perspective, supply chain and manufacturing systems will be the key variables determining how quickly the industry can scale. Compared with conventional oncology drugs, targeted PSMA radionuclide drug conjugates place much higher demands on isotope supply, specialized manufacturing facilities, quality release, time-sensitive distribution, and hospital nuclear medicine capabilities. In the future, leading companies are expected to continue strengthening delivery resilience by expanding radiopharmaceutical production sites, building regional manufacturing networks, and increasing treatment-center coverage. As a result, competition will no longer be limited to the drug itself, but will increasingly become competition in integrated capabilities spanning product, manufacturing, logistics, and hospital access. In other words, companies that establish stable isotope access and strong treatment networks earlier will be better positioned in the commercialization phase.
Nevertheless, the industry still faces several constraints. Stable isotope supply, the construction cycle of dedicated capacity, and the availability of specialized treatment centers remain practical bottlenecks to market expansion. In addition, patient treatment pathways usually rely on PSMA imaging selection and supporting nuclear medicine infrastructure, while reimbursement systems, hospital access, and treatment standards differ significantly across countries and regions, making global market expansion uneven. As the category moves into earlier treatment settings and addresses a broader patient population, requirements for safety management, treatment standardization, and long-term follow-up data will also continue to rise. Overall, targeted PSMA radionuclide drug conjugates offer clear long-term growth potential, but future expansion is more likely to be gradual and system-driven, supported jointly by clinical evidence, supply assurance, and healthcare infrastructure development, rather than by rapid short-term scaling.
This report is a detailed and comprehensive analysis for global Targeted PSMA Radionuclide Drug Conjugates market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Targeted PSMA Radionuclide Drug Conjugates market size and forecasts, in consumption value ($ Million), 2021-2032
Global Targeted PSMA Radionuclide Drug Conjugates market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Targeted PSMA Radionuclide Drug Conjugates market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Targeted PSMA Radionuclide Drug Conjugates market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Targeted PSMA Radionuclide Drug Conjugates
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Targeted PSMA Radionuclide Drug Conjugates market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Monotherapy Products
- Combination Therapy Products
- Beta-emitting
- Alpha-emitting
- Other
- Small-molecule
- Antibody-based
- Other
- Hospital
- Clinic
- Others
- Novartis
- Curium
- Telix Pharmaceuticals
- Lantheus
- Fusion Pharmaceuticals
- Blue Earth Therapeutics
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Targeted PSMA Radionuclide Drug Conjugates product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Targeted PSMA Radionuclide Drug Conjugates, with revenue, gross margin, and global market share of Targeted PSMA Radionuclide Drug Conjugates from 2021 to 2026.
Chapter 3, the Targeted PSMA Radionuclide Drug Conjugates competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Targeted PSMA Radionuclide Drug Conjugates market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Targeted PSMA Radionuclide Drug Conjugates.
Chapter 13, to describe Targeted PSMA Radionuclide Drug Conjugates research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Targeted PSMA Radionuclide Drug Conjugates by Type
1.3.1 Overview: Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type in 2025
1.3.3 Monotherapy Products
1.3.4 Combination Therapy Products
1.4 Classification of Targeted PSMA Radionuclide Drug Conjugates by Radionuclide Type
1.4.1 Overview: Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type: 2021 Versus 2025 Versus 2032
1.4.2 Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Radionuclide Type in 2025
1.4.3 Beta-emitting
1.4.4 Alpha-emitting
1.4.5 Other
1.5 Classification of Targeted PSMA Radionuclide Drug Conjugates by Targeting Vector Type
1.5.1 Overview: Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type: 2021 Versus 2025 Versus 2032
1.5.2 Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Targeting Vector Type in 2025
1.5.3 Small-molecule
1.5.4 Antibody-based
1.5.5 Other
1.6 Global Targeted PSMA Radionuclide Drug Conjugates Market by Application
1.6.1 Overview: Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Hospital
1.6.3 Clinic
1.6.4 Others
1.7 Global Targeted PSMA Radionuclide Drug Conjugates Market Size & Forecast
1.8 Global Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast by Region
1.8.1 Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Region, (2021-2032)
1.8.3 North America Targeted PSMA Radionuclide Drug Conjugates Market Size and Prospect (2021-2032)
1.8.4 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size and Prospect (2021-2032)
1.8.6 South America Targeted PSMA Radionuclide Drug Conjugates Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
2.1.4 Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Novartis Recent Developments and Future Plans
2.2 Curium
2.2.1 Curium Details
2.2.2 Curium Major Business
2.2.3 Curium Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
2.2.4 Curium Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Curium Recent Developments and Future Plans
2.3 Telix Pharmaceuticals
2.3.1 Telix Pharmaceuticals Details
2.3.2 Telix Pharmaceuticals Major Business
2.3.3 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
2.3.4 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Telix Pharmaceuticals Recent Developments and Future Plans
2.4 Lantheus
2.4.1 Lantheus Details
2.4.2 Lantheus Major Business
2.4.3 Lantheus Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
2.4.4 Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Lantheus Recent Developments and Future Plans
2.5 Fusion Pharmaceuticals
2.5.1 Fusion Pharmaceuticals Details
2.5.2 Fusion Pharmaceuticals Major Business
2.5.3 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
2.5.4 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Fusion Pharmaceuticals Recent Developments and Future Plans
2.6 Blue Earth Therapeutics
2.6.1 Blue Earth Therapeutics Details
2.6.2 Blue Earth Therapeutics Major Business
2.6.3 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
2.6.4 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Blue Earth Therapeutics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Targeted PSMA Radionuclide Drug Conjugates Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Targeted PSMA Radionuclide Drug Conjugates by Company Revenue
3.2.2 Top 3 Targeted PSMA Radionuclide Drug Conjugates Players Market Share in 2025
3.2.3 Top 6 Targeted PSMA Radionuclide Drug Conjugates Players Market Share in 2025
3.3 Targeted PSMA Radionuclide Drug Conjugates Market: Overall Company Footprint Analysis
3.3.1 Targeted PSMA Radionuclide Drug Conjugates Market: Region Footprint
3.3.2 Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Type Footprint
3.3.3 Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value and Market Share by Type (2021-2026)
4.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application (2021-2026)
5.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2032)
6.2 North America Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2032)
6.3 North America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
6.3.1 North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2032)
6.3.2 United States Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
6.3.3 Canada Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
6.3.4 Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2032)
7.2 Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2032)
7.3 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
7.3.1 Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2032)
7.3.2 Germany Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
7.3.3 France Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
7.3.5 Russia Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
7.3.6 Italy Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size by Region
8.3.1 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2021-2032)
8.3.2 China Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
8.3.3 Japan Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
8.3.4 South Korea Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
8.3.5 India Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
8.3.7 Australia Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2032)
9.2 South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2032)
9.3 South America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
9.3.1 South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2032)
9.3.2 Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
9.3.3 Argentina Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
10.3.1 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2032)
10.3.2 Turkey Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
10.3.4 UAE Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Targeted PSMA Radionuclide Drug Conjugates Market Drivers
11.2 Targeted PSMA Radionuclide Drug Conjugates Market Restraints
11.3 Targeted PSMA Radionuclide Drug Conjugates Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Targeted PSMA Radionuclide Drug Conjugates Industry Chain
12.2 Targeted PSMA Radionuclide Drug Conjugates Upstream Analysis
12.3 Targeted PSMA Radionuclide Drug Conjugates Midstream Analysis
12.4 Targeted PSMA Radionuclide Drug Conjugates Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Targeted PSMA Radionuclide Drug Conjugates by Type
1.3.1 Overview: Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type in 2025
1.3.3 Monotherapy Products
1.3.4 Combination Therapy Products
1.4 Classification of Targeted PSMA Radionuclide Drug Conjugates by Radionuclide Type
1.4.1 Overview: Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Radionuclide Type: 2021 Versus 2025 Versus 2032
1.4.2 Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Radionuclide Type in 2025
1.4.3 Beta-emitting
1.4.4 Alpha-emitting
1.4.5 Other
1.5 Classification of Targeted PSMA Radionuclide Drug Conjugates by Targeting Vector Type
1.5.1 Overview: Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Targeting Vector Type: 2021 Versus 2025 Versus 2032
1.5.2 Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Targeting Vector Type in 2025
1.5.3 Small-molecule
1.5.4 Antibody-based
1.5.5 Other
1.6 Global Targeted PSMA Radionuclide Drug Conjugates Market by Application
1.6.1 Overview: Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Hospital
1.6.3 Clinic
1.6.4 Others
1.7 Global Targeted PSMA Radionuclide Drug Conjugates Market Size & Forecast
1.8 Global Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast by Region
1.8.1 Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Region, (2021-2032)
1.8.3 North America Targeted PSMA Radionuclide Drug Conjugates Market Size and Prospect (2021-2032)
1.8.4 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size and Prospect (2021-2032)
1.8.6 South America Targeted PSMA Radionuclide Drug Conjugates Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
2.1.4 Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Novartis Recent Developments and Future Plans
2.2 Curium
2.2.1 Curium Details
2.2.2 Curium Major Business
2.2.3 Curium Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
2.2.4 Curium Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Curium Recent Developments and Future Plans
2.3 Telix Pharmaceuticals
2.3.1 Telix Pharmaceuticals Details
2.3.2 Telix Pharmaceuticals Major Business
2.3.3 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
2.3.4 Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Telix Pharmaceuticals Recent Developments and Future Plans
2.4 Lantheus
2.4.1 Lantheus Details
2.4.2 Lantheus Major Business
2.4.3 Lantheus Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
2.4.4 Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Lantheus Recent Developments and Future Plans
2.5 Fusion Pharmaceuticals
2.5.1 Fusion Pharmaceuticals Details
2.5.2 Fusion Pharmaceuticals Major Business
2.5.3 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
2.5.4 Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Fusion Pharmaceuticals Recent Developments and Future Plans
2.6 Blue Earth Therapeutics
2.6.1 Blue Earth Therapeutics Details
2.6.2 Blue Earth Therapeutics Major Business
2.6.3 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
2.6.4 Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Blue Earth Therapeutics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Targeted PSMA Radionuclide Drug Conjugates Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Targeted PSMA Radionuclide Drug Conjugates by Company Revenue
3.2.2 Top 3 Targeted PSMA Radionuclide Drug Conjugates Players Market Share in 2025
3.2.3 Top 6 Targeted PSMA Radionuclide Drug Conjugates Players Market Share in 2025
3.3 Targeted PSMA Radionuclide Drug Conjugates Market: Overall Company Footprint Analysis
3.3.1 Targeted PSMA Radionuclide Drug Conjugates Market: Region Footprint
3.3.2 Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Type Footprint
3.3.3 Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value and Market Share by Type (2021-2026)
4.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application (2021-2026)
5.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2032)
6.2 North America Targeted PSMA Radionuclide Drug Conjugates Market Size by Application (2021-2032)
6.3 North America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
6.3.1 North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2032)
6.3.2 United States Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
6.3.3 Canada Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
6.3.4 Mexico Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2032)
7.2 Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2032)
7.3 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
7.3.1 Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2032)
7.3.2 Germany Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
7.3.3 France Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
7.3.5 Russia Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
7.3.6 Italy Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size by Region
8.3.1 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2021-2032)
8.3.2 China Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
8.3.3 Japan Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
8.3.4 South Korea Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
8.3.5 India Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
8.3.7 Australia Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2032)
9.2 South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2032)
9.3 South America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
9.3.1 South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2032)
9.3.2 Brazil Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
9.3.3 Argentina Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
10.3.1 Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2032)
10.3.2 Turkey Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
10.3.4 UAE Targeted PSMA Radionuclide Drug Conjugates Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Targeted PSMA Radionuclide Drug Conjugates Market Drivers
11.2 Targeted PSMA Radionuclide Drug Conjugates Market Restraints
11.3 Targeted PSMA Radionuclide Drug Conjugates Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Targeted PSMA Radionuclide Drug Conjugates Industry Chain
12.2 Targeted PSMA Radionuclide Drug Conjugates Upstream Analysis
12.3 Targeted PSMA Radionuclide Drug Conjugates Midstream Analysis
12.4 Targeted PSMA Radionuclide Drug Conjugates Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Radionuclide Type, (USD Million), 2021 & 2025 & 2032
Table 3. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Targeting Vector Type, (USD Million), 2021 & 2025 & 2032
Table 4. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Novartis Company Information, Head Office, and Major Competitors
Table 8. Novartis Major Business
Table 9. Novartis Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
Table 10. Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Novartis Recent Developments and Future Plans
Table 12. Curium Company Information, Head Office, and Major Competitors
Table 13. Curium Major Business
Table 14. Curium Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
Table 15. Curium Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Curium Recent Developments and Future Plans
Table 17. Telix Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 18. Telix Pharmaceuticals Major Business
Table 19. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
Table 20. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Lantheus Company Information, Head Office, and Major Competitors
Table 22. Lantheus Major Business
Table 23. Lantheus Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
Table 24. Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Lantheus Recent Developments and Future Plans
Table 26. Fusion Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 27. Fusion Pharmaceuticals Major Business
Table 28. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
Table 29. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Fusion Pharmaceuticals Recent Developments and Future Plans
Table 31. Blue Earth Therapeutics Company Information, Head Office, and Major Competitors
Table 32. Blue Earth Therapeutics Major Business
Table 33. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
Table 34. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Blue Earth Therapeutics Recent Developments and Future Plans
Table 36. Global Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million) by Players (2021-2026)
Table 37. Global Targeted PSMA Radionuclide Drug Conjugates Revenue Share by Players (2021-2026)
Table 38. Breakdown of Targeted PSMA Radionuclide Drug Conjugates by Company Type (Tier 1, Tier 2, and Tier 3)
Table 39. Market Position of Players in Targeted PSMA Radionuclide Drug Conjugates, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 40. Head Office of Key Targeted PSMA Radionuclide Drug Conjugates Players
Table 41. Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Type Footprint
Table 42. Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Application Footprint
Table 43. Targeted PSMA Radionuclide Drug Conjugates New Market Entrants and Barriers to Market Entry
Table 44. Targeted PSMA Radionuclide Drug Conjugates Mergers, Acquisition, Agreements, and Collaborations
Table 45. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value (USD Million) by Type (2021-2026)
Table 46. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Share by Type (2021-2026)
Table 47. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Forecast by Type (2027-2032)
Table 48. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2026)
Table 49. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Forecast by Application (2027-2032)
Table 50. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 51. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 52. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 53. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 54. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 55. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 56. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 57. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 58. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 59. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 60. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 61. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 62. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 63. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 64. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 65. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 66. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)
Table 67. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2027-2032) & (USD Million)
Table 68. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 69. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 70. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 71. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 72. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 73. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 74. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 75. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 76. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 77. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 78. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 79. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 80. Global Key Players of Targeted PSMA Radionuclide Drug Conjugates Upstream (Raw Materials)
Table 81. Global Targeted PSMA Radionuclide Drug Conjugates Typical Customers
Table 1. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Radionuclide Type, (USD Million), 2021 & 2025 & 2032
Table 3. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Targeting Vector Type, (USD Million), 2021 & 2025 & 2032
Table 4. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Novartis Company Information, Head Office, and Major Competitors
Table 8. Novartis Major Business
Table 9. Novartis Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
Table 10. Novartis Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Novartis Recent Developments and Future Plans
Table 12. Curium Company Information, Head Office, and Major Competitors
Table 13. Curium Major Business
Table 14. Curium Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
Table 15. Curium Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Curium Recent Developments and Future Plans
Table 17. Telix Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 18. Telix Pharmaceuticals Major Business
Table 19. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
Table 20. Telix Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Lantheus Company Information, Head Office, and Major Competitors
Table 22. Lantheus Major Business
Table 23. Lantheus Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
Table 24. Lantheus Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Lantheus Recent Developments and Future Plans
Table 26. Fusion Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 27. Fusion Pharmaceuticals Major Business
Table 28. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
Table 29. Fusion Pharmaceuticals Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Fusion Pharmaceuticals Recent Developments and Future Plans
Table 31. Blue Earth Therapeutics Company Information, Head Office, and Major Competitors
Table 32. Blue Earth Therapeutics Major Business
Table 33. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Product and Solutions
Table 34. Blue Earth Therapeutics Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Blue Earth Therapeutics Recent Developments and Future Plans
Table 36. Global Targeted PSMA Radionuclide Drug Conjugates Revenue (USD Million) by Players (2021-2026)
Table 37. Global Targeted PSMA Radionuclide Drug Conjugates Revenue Share by Players (2021-2026)
Table 38. Breakdown of Targeted PSMA Radionuclide Drug Conjugates by Company Type (Tier 1, Tier 2, and Tier 3)
Table 39. Market Position of Players in Targeted PSMA Radionuclide Drug Conjugates, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 40. Head Office of Key Targeted PSMA Radionuclide Drug Conjugates Players
Table 41. Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Type Footprint
Table 42. Targeted PSMA Radionuclide Drug Conjugates Market: Company Product Application Footprint
Table 43. Targeted PSMA Radionuclide Drug Conjugates New Market Entrants and Barriers to Market Entry
Table 44. Targeted PSMA Radionuclide Drug Conjugates Mergers, Acquisition, Agreements, and Collaborations
Table 45. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value (USD Million) by Type (2021-2026)
Table 46. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Share by Type (2021-2026)
Table 47. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Forecast by Type (2027-2032)
Table 48. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2026)
Table 49. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Forecast by Application (2027-2032)
Table 50. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 51. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 52. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 53. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 54. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 55. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 56. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 57. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 58. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 59. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 60. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 61. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 62. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 63. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 64. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 65. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 66. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)
Table 67. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Region (2027-2032) & (USD Million)
Table 68. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 69. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 70. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 71. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 72. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 73. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 74. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2021-2026) & (USD Million)
Table 75. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type (2027-2032) & (USD Million)
Table 76. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2021-2026) & (USD Million)
Table 77. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application (2027-2032) & (USD Million)
Table 78. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2021-2026) & (USD Million)
Table 79. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Country (2027-2032) & (USD Million)
Table 80. Global Key Players of Targeted PSMA Radionuclide Drug Conjugates Upstream (Raw Materials)
Table 81. Global Targeted PSMA Radionuclide Drug Conjugates Typical Customers
LIST OF FIGURES
Figure 1. Targeted PSMA Radionuclide Drug Conjugates Picture
Figure 2. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type in 2025
Figure 4. Monotherapy Products
Figure 5. Combination Therapy Products
Figure 6. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Radionuclide Type, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Radionuclide Type in 2025
Figure 8. Beta-emitting
Figure 9. Alpha-emitting
Figure 10. Other
Figure 11. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Targeting Vector Type, (USD Million), 2021 & 2025 & 2032
Figure 12. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Targeting Vector Type in 2025
Figure 13. Small-molecule
Figure 14. Antibody-based
Figure 15. Other
Figure 16. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 17. Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application in 2025
Figure 18. Hospital Picture
Figure 19. Clinic Picture
Figure 20. Others Picture
Figure 21. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 22. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 23. Global Market Targeted PSMA Radionuclide Drug Conjugates Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 24. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Region (2021-2032)
Figure 25. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Region in 2025
Figure 26. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 27. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 28. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 29. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 30. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 31. Company Three Recent Developments and Future Plans
Figure 32. Global Targeted PSMA Radionuclide Drug Conjugates Revenue Share by Players in 2025
Figure 33. Targeted PSMA Radionuclide Drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 34. Market Share of Targeted PSMA Radionuclide Drug Conjugates by Player Revenue in 2025
Figure 35. Top 3 Targeted PSMA Radionuclide Drug Conjugates Players Market Share in 2025
Figure 36. Top 6 Targeted PSMA Radionuclide Drug Conjugates Players Market Share in 2025
Figure 37. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Share by Type (2021-2026)
Figure 38. Global Targeted PSMA Radionuclide Drug Conjugates Market Share Forecast by Type (2027-2032)
Figure 39. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Share by Application (2021-2026)
Figure 40. Global Targeted PSMA Radionuclide Drug Conjugates Market Share Forecast by Application (2027-2032)
Figure 41. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 42. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 43. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 44. United States Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 45. Canada Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 46. Mexico Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 47. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 48. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 49. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 50. Germany Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 51. France Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 52. United Kingdom Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 53. Russia Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 54. Italy Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 55. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 56. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 57. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Region (2021-2032)
Figure 58. China Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 59. Japan Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 60. South Korea Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 61. India Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 62. Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 63. Australia Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 64. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 65. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 66. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 67. Brazil Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 68. Argentina Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 69. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 70. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 71. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 72. Turkey Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 73. Saudi Arabia Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 74. UAE Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 75. Targeted PSMA Radionuclide Drug Conjugates Market Drivers
Figure 76. Targeted PSMA Radionuclide Drug Conjugates Market Restraints
Figure 77. Targeted PSMA Radionuclide Drug Conjugates Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Targeted PSMA Radionuclide Drug Conjugates Industrial Chain
Figure 80. Methodology
Figure 81. Research Process and Data Source
Figure 1. Targeted PSMA Radionuclide Drug Conjugates Picture
Figure 2. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type in 2025
Figure 4. Monotherapy Products
Figure 5. Combination Therapy Products
Figure 6. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Radionuclide Type, (USD Million), 2021 & 2025 & 2032
Figure 7. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Radionuclide Type in 2025
Figure 8. Beta-emitting
Figure 9. Alpha-emitting
Figure 10. Other
Figure 11. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Targeting Vector Type, (USD Million), 2021 & 2025 & 2032
Figure 12. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Targeting Vector Type in 2025
Figure 13. Small-molecule
Figure 14. Antibody-based
Figure 15. Other
Figure 16. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 17. Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application in 2025
Figure 18. Hospital Picture
Figure 19. Clinic Picture
Figure 20. Others Picture
Figure 21. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 22. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 23. Global Market Targeted PSMA Radionuclide Drug Conjugates Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 24. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Region (2021-2032)
Figure 25. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Region in 2025
Figure 26. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 27. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 28. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 29. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 30. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 31. Company Three Recent Developments and Future Plans
Figure 32. Global Targeted PSMA Radionuclide Drug Conjugates Revenue Share by Players in 2025
Figure 33. Targeted PSMA Radionuclide Drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 34. Market Share of Targeted PSMA Radionuclide Drug Conjugates by Player Revenue in 2025
Figure 35. Top 3 Targeted PSMA Radionuclide Drug Conjugates Players Market Share in 2025
Figure 36. Top 6 Targeted PSMA Radionuclide Drug Conjugates Players Market Share in 2025
Figure 37. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Share by Type (2021-2026)
Figure 38. Global Targeted PSMA Radionuclide Drug Conjugates Market Share Forecast by Type (2027-2032)
Figure 39. Global Targeted PSMA Radionuclide Drug Conjugates Consumption Value Share by Application (2021-2026)
Figure 40. Global Targeted PSMA Radionuclide Drug Conjugates Market Share Forecast by Application (2027-2032)
Figure 41. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 42. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 43. North America Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 44. United States Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 45. Canada Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 46. Mexico Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 47. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 48. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 49. Europe Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 50. Germany Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 51. France Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 52. United Kingdom Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 53. Russia Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 54. Italy Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 55. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 56. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 57. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Region (2021-2032)
Figure 58. China Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 59. Japan Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 60. South Korea Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 61. India Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 62. Southeast Asia Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 63. Australia Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 64. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 65. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 66. South America Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 67. Brazil Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 68. Argentina Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 69. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Type (2021-2032)
Figure 70. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Application (2021-2032)
Figure 71. Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Consumption Value Market Share by Country (2021-2032)
Figure 72. Turkey Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 73. Saudi Arabia Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 74. UAE Targeted PSMA Radionuclide Drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 75. Targeted PSMA Radionuclide Drug Conjugates Market Drivers
Figure 76. Targeted PSMA Radionuclide Drug Conjugates Market Restraints
Figure 77. Targeted PSMA Radionuclide Drug Conjugates Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Targeted PSMA Radionuclide Drug Conjugates Industrial Chain
Figure 80. Methodology
Figure 81. Research Process and Data Source
